Provenienza dei contatti di primo grado di Timothy Schulz-Utermoehl
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Pencil Biosciences Ltd.
 Pencil Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Pencil Biosciences Ltd. develops gene modulation technology. The company was founded on November 5, 2018 and is headquartered in Macclesfield, the United Kingdom.
3
| Holding Company | Miscellaneous Commercial Services | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Timothy Schulz-Utermoehl tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Chief Executive Officer | |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
Epitopea Ltd.
 Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Miscellaneous Commercial Services | Founder | |
| Alliance Manchester Business School | College/University | Masters Business Admin | |
| The School of Pharmacy University of London | College/University | Doctorate Degree | |
| University of Strathclyde | College/University | Undergraduate Degree | |
| Pandeia Therapeutics Ltd. | Founder | ||
| Hummingbird UK Partners Ltd. | Investment Managers | Private Equity Investor | |
| University of London | College/University | Graduate Degree | |
| University of Cambridge | College/University | Graduate Degree | |
Midven Ltd.
 Midven Ltd. Investment ManagersFinance Midven Ltd (Midven) is a venture capital firm founded in 1990. The firm is headquartered in Birmingham, United Kingdom. | Investment Managers | Private Equity Investor | |
Aston Tower Multi-Academy Trust
 Aston Tower Multi-Academy Trust Investment Trusts/Mutual FundsMiscellaneous Aston Tower Multi-Academy Trust is a British educational institution management company founded in 2016. The non-profit company is based in Birmingham, UK. The company manages educational institutions. | Investment Trusts/Mutual Funds | Director/Board Member | |
| University of Birmingham | College/University | Doctorate Degree | |
Avvinity Therapeutics Ltd.
 Avvinity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples. | Pharmaceuticals: Major | Founder | |
| HORIZON DISCOVERY GROUP PLC | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| Newcastle University | College/University | Doctorate Degree | |
Horizon Discovery Ltd.
 Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Incenta Ltd. | Corporate Officer/Principal | ||
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Biotechnology | Corporate Officer/Principal | |
| University of Portsmouth | College/University | Undergraduate Degree | |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member |
Statistiche
Distribuzione geografica
| Regno Unito | 22 |
| Lettonia | 2 |
| Francia | 2 |
Settori
| Consumer Services | 9 |
| Commercial Services | 5 |
| Health Technology | 5 |
| Finance | 4 |
| Miscellaneous | 2 |
Posizioni
| Director/Board Member | 9 |
| Corporate Officer/Principal | 5 |
| Founder | 5 |
| Chief Executive Officer | 5 |
| Chief Tech/Sci/R&D Officer | 4 |
Contatti più connessi
| Insiders | |
|---|---|
| Jonathan Moore | 9 |
| Fraser Murray | 8 |
| Martin Quibell | 7 |
| Pablo Lubroth | 5 |
| Rajik Ibrahim | 1 |
- Borsa valori
- Insiders
- Timothy Schulz-Utermoehl
- Connessioni Società
